HJNO Jul/Aug 2025

HEALTHCARE JOURNAL OF NEW ORLEANS I  JUL / AUG 2025 51 489 Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ. 2006 Jun 17;332(7555):1444-7. 490 Liu, J. J., Bell, C. M., Matelski, J. J., Detsky, A. S., & Cram, P. (2017). Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. bmj, 359. 491 Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies. Plos medicine, 2(5), e138. 492 Lexchin, J., & Light, D. W. (2006). Commercial influence and the content of medical journals. Bmj, 332(7555), 1444-1447. 493 Wouters, O. J. (2020). Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018. JAMA Internal Medicine, 180(5), 688-697. 494 Kaiser Health News. (2018). “Pre$cription for Power: Patient Advocacy Groups Take In Millions From Drugmakers. Is There a Payoff?” Retrieved from KHN Pre$cription for Power. 495 Pradhan R, (2025 , January 17 ). More than two-thirds of patient advocacy groups studied received funding from drug, medical device companies. Millions of dollars flow from pharma to patient advocacy groups. KFF Health News. https://kffhealthnews.org/news/article/health-202-pharma-money-patient-advocacy-groups-public- citizen/. 496 Foley, K. E. (2022, July 21) (2019, July) . Trust issues deepen as yet another FDA commissioner joins the pharmaceutical industry. Quartz. https://qz.com/1656529/ yet-another-fda-commissioner-joins-the-pharmaceutical-industry. 497 Piller, C. (2018). FDA’s revolving door: Companies often hire agency staffers who managed their successful drug reviews. Science. Retrieved from https://www.science . org/content/article/fda-s-revolving-door-companies-often-hire-agency-staffers-who-managed-their-successful. 498 Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic-industry relationships. JAMA. 2007;298(15):1779-1786. 499 Angell, M. (2004). The Truth About the Drug Companies: How They Deceive Us and What to Do About It. Random House. 500 Brody, H. (2009). Pharmaceutical industry financial support for medical education: Benefit, or undue influence? Journal of Law, Medicine & Ethics, 37(3), 451–460. https://doi.org/10.1111/j.1748-720X.2009.00407 doi:10.1111/j.1748-720X.2009.00406.x. 501 Fugh-Berman, A. (2021). Industry-funded medical education is always promotion. BMJ, 373, n1273. 502 Healy, M. (2007, August 6). In short, marketing works. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2007-aug-06-he- effectiveness6-story.html. 503 Jeanne Lenzer, “Centers for Disease Control and Prevention: protecting the private good?” BMJ, May 15, 2015. 504 CDC Foundation. (n.d.). Take Action. Retrieved May 15, 2025, from https://www.cdcfoundation.org/take-action. 505 Lenzer, J. (2015). Centers for Disease Control and Prevention: protecting the private good?. bmj, 350. 506 Neuman, J., Korenstein, D., Ross, J. S., & Keyhani, S. (2011). Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: Cross-sectional study. BMJ, 343, d5621. 507 Hunt, L. M., Arndt, E. A., Bell, H. S., & Howard, H. A. (2021). Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs. Journal of Bioethical Inquiry, 18(3), 477-497. 508 Lean, M. E. J., et al. (2023). Management of Type 2 Diabetes: ADA Standards of Medical Care in Diabetes. Diabetes Care, 46(Suppl 1), S1-S292. Woolston, C. (2019, March 6). The war on ‘prediabetes’ could be a boon for pharma—but is it good medicine? Science. https://www.science.org/content/article/war-prediabetes-could-be- boon-pharma-it-good-medicine. 509 Cosgrove, L., Bursztajn, H. J., Erlich, D. R., Wheeler, E. E., & Shaughnessy, A. F. (2014). Tripartite conflicts of interest and high stakes patent extensions in the DSM-5. Psychotherapy and Psychosomatics, 83(5), 272–278. 510 https://w.astro.berkeley.edu/~kalas/ethics/documents/ethics/Researchers%20Fail%20to%20Reveal%20Full%20Drug%20Pay%20-%20NYTimes.com.pdf . Harris, G., & Carey, B. (2008, June 8). Researchers fail to reveal full drug pay. The New York Times. https://www.nytimes.com/2008/06/08/us/08conflict.html. 511 Frances, A. (2013). Saving Normal: An Insider’s Revolt Against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life. William Morrow. 512 U.S. Department of Justice. (2004). Warner-Lambert to Pay $430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion. DOJ Press Release. Retrieved from justice.gov. 513 U.S. Department of Justice. (2013, November 4). Johnson & Johnson to pay more than $2.2 billion to resolve criminal and civil investigations [Press release] https:// www.justice.gov/archives/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations. 514 Goodnough, A. Thomas, K., & Schmidt, M. S. (2012, July 2). Glaxo agrees to pay $3 billion in fraud settlement. The New York Times. https://www.nytimes.com/2012/07/03/ business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html. 515 Toop, L., & Mangin, D. (2007). Industry funded patient information and the slippery slope to New Zealand. BMJ, 335(7622), 694–695. 516 Bulik, B. S. (2025, January 17). Can the Trump 2.0 administration cancel pharma marketers’ $5 billion TV ad spending? Marketing & Pharma. https://marketingandpharma. com/can-the-trump-2-0-administration-cancel-pharma-marketers-5-billion-tv-ad-spending/. 517 Layton, J. B., et al. (2017). Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA, 317(11), 1159-1166. 518 Hollon, M. F. (2006). Direct-to-consumer advertising: A haphazard approach to health promotion. The American Journal of Managed Care, 12(4), 225-230. 519 Woloshin, S., & Schwartz, L. M. (2008). Giving legs to restless legs: A case study of how the media helps make people sick. The New England Journal of Medicine, 358(8), 839-841. 520 Mintzes, B. (2005). Kravitz, R. L. (2000). Direct-to-consumer advertising of prescription drugs: Implications for the patient-physician relationship. The Lancet, 366(9487), 789-791. JAMA, 284(17),2244-2244. doi:10.1001/jama.284.17.2244-JMS1101-5-1. 521 Shah, M. B., et al. (2008). Direct-to-consumer advertising and the rise in ADHD medication use among children. Pediatrics, 122(5), e1055-e1060. Schwarz, A. (2013, December 14). The Selling of Attention Deficit Disorder. The New York Times. https://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html. 522 Findling, R. L., et al. (2009). Direct-to-consumer advertising of psychotropic medications for youth: A growing concern. Journal of Child and Adolescent Psychopharmacology, 19(5), 487-492. Thomas, C. P., Conrad, P., Casler, R., & Goodman, E. (2006). Trends in the Use of Psychotropic Medications Among Adolescents, 1994 to 2001. Psychiatric Services, 57(1), 63–69. https://doi.org/10.1176/appi.ps.57.1.63.